Rezolute, Inc.
HealthcareNASDAQ:RZLT · NASDAQ Capital Market
+$0.14 today
Vol 1.31M · Avg 2.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-45.9%
avg -186.0%
ROIC
-48.7%
avg 691.4%
ROA
-42.4%
avg -206.1%
Analysis
ROA is currently the strongest return metric at -42.4% versus its period average of -206.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Nevan Charles Elam | Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board | $1.08M | — | 59 | $613,501.00 | 0.64% |
Brian Kenneth Roberts | Chief Medical Officer | $767,526.00 | — | 50 | $296,913.00 | 0.31% |
Daron G. Evans | Chief Financial & Business Officer | $699,209.00 | — | 52 | $414,462.00 | 0.43% |
Raj Agrawal | Vice President & Head of Ophthalmological Clinical Development | — | — | — | — | — |
Chris Milks | Vice President & Head of Finance | — | — | — | — | — |
Melissa Quinn | Senior Director of People and Culture | — | — | — | — | — |
Robyn Sweinhart | Vice President & Head of Quality | — | — | — | — | — |
Davelyn Eaves Hood | Director and Head of Scientific & Patient Affairs | — | — | — | — | — |
Michael Covarrubias | Senior Vice President & Head of Program & Portfolio Management | — | — | — | $300,000.00 | 0.31% |
Michael R. Deperro | Senior VP & Head of Operations | — | — | — | $300,000.00 | 0.31% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$4.33M
Sells
0
$0.00
Net Sentiment
+$4.33M
Net buying
Most Active
Evans Daron
6 transactions
1–10 of 14
Analysis
Insiders reported 14 buys worth $4.33M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $4.33M. Evans Daron was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Geron Corporation
NASDAQ:GERN
$737.75M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
ProKidney Corp.
NASDAQ:PROK
$242.99M
Who manages RZLT?
Rezolute, Inc. (RZLT) lists 10 active executives. The top listed executive is Daron G. Evans, Chief Financial & Business Officer.
Are RZLT insiders buying or selling?
Recent insider activity shows net buying of $43.47M.
Explore More
Continue the stock analysis
Jump to another research area for this company.